The World Health Organization is advancing plans to launch a clinical trial of an Ebola vaccine in the Democratic Republic of Congo, where a fast-moving outbreak has already killed more than 2,000 people.

The epidemic in DRC’s Ituri province — near the Uganda and South Sudan borders — has topped 4,500 confirmed cases and 2,060 deaths, making it the second-largest Ebola epidemic on record and one spreading faster than previous ones.

“At its current pace, it’s on track to eclipse the West African Ebola outbreak of 2014–2016,” said WHO Director-General Tedros Adhanom Ghebreyesus.

Why the pace matters more than the total

The West African epidemic remains the largest on record, and it unfolded over roughly two years. An outbreak reaching this scale faster indicates either more effective transmission or less effective containment — and probably both.

Ituri’s location compounds it. The province borders two countries, and cross-border movement makes containment substantially harder: contact tracing that works within a health district breaks down when contacts cross into another jurisdiction with different surveillance and different authorities.

Eastern DRC has also experienced prolonged conflict and displacement, which disrupts health services, complicates access for response teams and generates population movement that spreads infection.

Why vaccinate during an outbreak at all

Ebola vaccination is inherently reactive. The disease appears in episodic outbreaks rather than circulating continuously, so there is no stable population to vaccinate preventively at scale — and vaccine deployment therefore happens during emergencies, under exactly the conditions least suited to running a trial.

The first vaccine to be tested is Merck’s Ervebo, which targets the Ebola Zaire species — a product already licensed and used in previous outbreaks.

The methodological change

Rather than the ring vaccination approach used before, the trial would individually randomise known contacts of cases to vaccine or placebo, which WHO’s Vasee Moorthy said is “more efficient.”

Ring vaccination targets everyone around a confirmed case — contacts, and contacts of contacts — on the reasoning that transmission occurs in clusters, so vaccinating the ring interrupts spread. It was used to demonstrate Ebola vaccine efficacy previously, with rings randomised to immediate or delayed vaccination rather than individuals to vaccine or placebo.

Randomising individuals is statistically more efficient, because each person contributes independently rather than the analysis being constrained by the number of rings. That means fewer participants for the same statistical power — which matters when enrolment happens during an emergency.

The trade-off in that change

It also means giving placebo to identified contacts of Ebola cases, which is ethically more demanding than the ring design.

The delayed-vaccination ring approach was chosen partly because it avoided withholding a potentially protective intervention entirely — everyone was vaccinated, some later. Individual randomisation to placebo means some high-risk contacts receive nothing.

That is defensible where the vaccine’s benefit in this specific context is genuinely uncertain, and it is not a costless design choice. Submitting the Phase 3 protocol to DRC regulatory and ethics committees is where that judgement gets made, appropriately by the country bearing the outbreak.

The strain problem

Ervebo targets Ebola Zaire specifically, and species matter enormously here.

Ebolaviruses comprise several distinct species, and immunity to one does not reliably protect against another. An outbreak caused by Sudan or Bundibugyo virus would render a Zaire-targeted vaccine essentially useless — which has happened, leaving responders without a vaccine option.

That is why the pipeline matters: the Oxford Vaccine Group with the Serum Institute and IAVI are developing vaccines for the Bundibugyo strain, and Moderna has a Phase 1 mRNA Ebola vaccine trial underway in Canada with early results expected in September 2026.

Why mRNA is interesting for this specifically

The platform’s advantage in outbreak response is speed of reformulation. If a vaccine can be redesigned against a different species in weeks rather than years, the strain-mismatch problem becomes considerably more tractable.

Whether that translates in practice depends on manufacturing and regulatory timelines rather than the technology alone — but for a disease appearing unpredictably in several distinct species, a platform that can be pointed at whichever one emerges is exactly what the response has lacked.

What made the 2014 outbreak so instructive

The comparison Tedros drew is not rhetorical — the West African epidemic reshaped how the world responds to these events, and its lessons explain the urgency here.

That outbreak reached more than 28,000 cases and over 11,000 deaths, spreading across three countries before the international response mobilised at scale. It escaped early containment partly because it appeared in a region with no previous Ebola experience, so cases were initially misattributed to other febrile illnesses.

The response ultimately worked, and it arrived late. The vaccine now being deployed was tested in the closing phase of that epidemic, when case numbers had already fallen — which is why the efficacy evidence was harder to generate than it should have been.

The lesson institutionalised since is that trials must be ready to launch when an outbreak begins rather than being designed once it is underway. A protocol submitted while cases are still rising is considerably better than the alternative, and it is still slower than a pre-approved protocol activated on day one would be.

For now, the priority is getting a proven tool into a worsening emergency as quickly as regulators allow. Public health news, not medical advice.